David R. Spigel, MD, FASCO
@DavidRSpigel
Followers
3K
Following
5K
Media
13
Statuses
115
Chief Scientific Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch
Nashville, TN
Joined March 2011
@SCRIOncology was honored to co-host the @AmericanCancer ACS gala in Nashville. Amazing fundraising effort benefitting patients facing cancer. @DavidRSpigel
@MLJohnsonMD2
@MeredithMcKean
@ErikaHamilton9
@BGarmezy
@MeredithPelster
@SPremji7866
@SarahCannonDocs
0
5
8
🎪 🤡 🐘 🦁 Happy Halloween from the circus! @MLJohnsonMD2 @DavidRSpigel @VivekSubbiah @BurrisSkip @SarahCannonDocs
0
1
10
🚨🚀Pleased to shared with the Universe 👉HOT OFF THE PRESS👉Simultaneously published with the NEW #ESMO25 @myESMO Tumour Agnostic Tack👉 "Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine" @AACR journal @CD_AACR @OncoAlert 👉 Read this paper that will
5
21
62
📅 We're counting down until #ESMO25 kicks off in Berlin tomorrow! 🗨️ Don't miss this interview with @StephenVLiu, who discusses anticipated thoracic oncology highlights of the meeting! ➡️ Watch now: https://t.co/vDhg8z8vxA
#lcsm #NSCLC #SCLC #ESMO2025 @myESMO
0
4
12
Honored to represent @ASCO and @SarahCannonDocs at the JSCO 2025 conference in Tokyo. We had an amazing conversation about ctDNA in perioperative oncology. I look forward to even more data coming at #ESMO25 #esmo2025
2
1
19
Dr. Hans Lee & Dr. Kris Patel from @SCRIoncology share how new therapies like CAR T-cell treatment are changing lives. 📺 Watch the full @NC5 segment here: https://t.co/9re1S73O9E
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI
0
1
4
Congratulations!! Well deserved Stephen!
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
1
0
17
NEW in @OncogeneJournal: @MiNK_iNKT reports complete remission in metastatic, SOC + ICI-refractory testicular cancer with allo-iNKT (agenT-797) ✔️ Durable survival ✔️ No lymphodepletion ✔️ No GVHD 🔗 Builds on 2L gastric PFS + >12mo OS @Nature
nature.com
Oncogene - Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
3
3
25
Excited to share a story about the power of clinical trials! Please see our article on oncogene examining a robust and durable response with iNKT cell therapy in a patient with very refractory germ cell tumor. @SarahCannonDocs and @SCRIOncology
https://t.co/zkR8pOI3SU
nature.com
Oncogene - Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
1
2
17
Dr. Joyce O’Shaughnessy delivering perfect update in advanced breast cancer research at #MLSNashville #ASCO25 meeting @SarahCannonDocs
2
0
8
Happening now at #ASCO25! Dr. Naqash serves as chair during the Oral Abstract Session: Lung Cancer-Non- Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session.
0
3
21
Happy to present Stellar-002 phase 1b study with zanzalitinib (tki) + nivo or Nivo/rela. Add to the front line RCC data presented by @JadChahoud. Compelling activity and durability in a pre treated population! #ASCO25 @SarahCannonDocs lots of hard work and thanks to the patients!
1
4
27
Shout out to @ErikaHamilton9 for making sure to pronounce the names of all the speakers in #ASCO25 Plenary Session correctly (and not just the easy ones like “Mark Lewis” @marklewismd😊). It’s a small thing, but shows respect when you care enough to do it right.
3
8
66
#ASCO25 🆒study acting on molecular progression noted on #ctDNA🩸🧬 ahead of radiographic disease progression - herein this was in patients with breast cancer. 💡Good utility of liquid biopsies if you have an actionable marker➕effective drugs. 📍Plenary session. @OncoAlert
2
12
20
Amazing data! Congratulations! Impactful today!!#ASCO25
1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?
0
1
5
SCRI is proud to contribute to the bold science and deep collaboration on display at #ASCO25. Our team is advancing clinical research brings hope to patients and loved ones everywhere. Explore our prescence: https://t.co/7cNuBexQ3s
@DavidRSpigel
3
0
6
So proud of this Star 🌟! You're going to be seeing more of Dr. Sarah Premji #bcsm community! #ASCO25 @SPremji7866 @Dee_Anna_Smith @DavidRSpigel @SCRIOncology @SarahCannonDocs
0
2
10
April is #TesticularCancerAwarenessMonth! Dr. @BGarmezy from @SCRIOncology stresses the importance of self-exams and shares breakthroughs in treatment. Let's spread awareness! 🔬 Read more:
newschannel5.com
Testicular cancer mostly affects young and middle-aged men, with an average diagnosis age of 33. In the US, testicular cancer cases are expected to reach 9,720 this year.
0
2
5
Come check out our poster on AR mutations and survival in a real world population at #GU25 #ASCOGU25. Great data from our Genospace team and resident Rikki Williams! B19. @SarahCannonDocs @mkbupathi @MarkTFlemingMD1 @VivekSubbiah @DavidRSpigel
0
5
25